BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
IBRX upcoming catalysts
ImmunityBio, Inc.: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 4 readout(s) and 0 FDA event(s). Subscribe to IBRX (.ics).
Drugs: BCG, Gemcitabine
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No upcoming PDUFA date or AdCom found. | |||||
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| No trials in this window. | ||||||
FDA decision events, last 12 months
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| No FDA decision events in this window. | |||||
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-15 est. | P2 | ImmunityBio, Inc. IBRX | NCT07492888 Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) | Acute Respiratory Distress Syndrome; Severe Community-Acquired Pneum; Sepsis; Lymphopenia / Immunopa | withdrawn | |
| 2026-11 est. | P2 | ImmunityBio, Inc. IBRX | NCT06829823 Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | Non-muscle Invasive Bladder Cancer (NMIBC) | not yet recruiting | 20 |
| 2026-10 est. | P2 | ImmunityBio, Inc. IBRX | NCT07108036 A Study to Assess Anktiva in Patients With Long Covid-19. | Long COVID | recruiting | 20 |
| 2026-09-30 est. | P1/P2 | ImmunityBio, Inc. IBRX | NCT02138734 A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | Non-muscle Invasive Bladder Cancer | active not recruiting | 369 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.